Tanvex BioPharma
Vertically integrated development and manufacturing for biopharmaceuticals.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
* | N/A | Post IPO Equity | |
| Total Funding | 000k | ||
| TWD | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | - | - | 1702 % | 314 % | 174 % | (44 %) |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | - | - | (621745 %) | (23185 %) | (5824 %) | (2857 %) | (2996 %) |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | - | - | (701412 %) | (28546 %) | (7325 %) | (3480 %) | (3984 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | - | - | 620200 % | 25592 % | 6032 % | 2779 % | 3052 % |
Source: Company filings or news article
Tanvex BioPharma is a biopharmaceutical company specializing in the research, development, and manufacturing of biosimilar products and offering contract development and manufacturing organization (CDMO) services. The company was founded by Dr. Allen Chao, who previously founded Watson Pharmaceuticals and pioneered the generic drug industry. Dr. Chao's vision for Tanvex is to apply the same principles of increasing availability and affordability to biopharmaceuticals, including biologics and biosimilars.
Tanvex operates as a vertically integrated company with end-to-end capabilities, from research and development to commercialization. This model provides control over the entire process, including cell line development in its Taiwan lab and downstream activities like purification and packaging in its U.S. facility. The company's facilities are equipped to handle both mammalian and microbial cell lines and have been inspected by the U.S. Food and Drug Administration (FDA). In October 2023, Tanvex launched Tanvex CDMO to provide its services to a broader audience, assisting small and mid-size biopharmaceutical companies in bringing their products from concept to market.
The company's business model focuses on two main areas: developing its own pipeline of biosimilar drugs and providing CDMO services to other biopharma companies. Its product pipeline includes treatments targeting conditions like neutropenia, breast cancer, and colorectal cancer. In June 2024, Tanvex received FDA market approval for its biosimilar drug TX01 (Nypozi), a treatment for neutropenia, marking a significant milestone for the company. The company has entered into a strategic alliance with Bora Pharmaceuticals, which is expected to conclude in the first quarter of 2025, to enhance its global CDMO capabilities.
Keywords: biopharmaceutical, biosimilars, contract development manufacturing organization, CDMO, vertical integration, biologics, cell line development, GMP manufacturing, mammalian cell culture, microbial fermentation, FDA approved, drug development, protein purification, biotherapeutics, neutropenia, oncology, pharmaceutical manufacturing, process development, analytical development, regulatory support